Redmile Biopharma Investments II, L.P. — Form D/A
Redmile Biopharma Investments II, L.P. of San Francisco, CA, a pooled investment fund, filed a Form D amendment with the SEC on 2020-03-05. The offering totals $675.4M, of which $675.4M was reported sold. Industry: Pooled Investment Fund.
Offering
- Filed: 2020-03-05
- Form: D/A
- Accession: 0001772230-20-000002
- Industry: Pooled Investment Fund
- Exemptions: 06b, 3C, 3C.7
- Total offering: $675.4M
- Amount sold: $675.4M
- Investors: 137
- Date of first sale: 2019-03-22
- Security types: fund interests
- Revenue range: Decline to Disclose
- SEC file number: 021-335974
Issuer
- Name: Redmile Biopharma Investments II, L.P.
- CIK: 0001772230
- Entity type: Limited Partnership
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: Letterman Digital Arts Center, San Francisco, CA, 94129
- Phone: 415-489-9980
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Jeremy Green | Executive Officer | New York, NY |
| Mike Lee | Executive Officer | Palo Alto, CA |
| Amrit Nagpal | Executive Officer | South San Francisco, CA |
| n/a Redmile Group, LLC | Executive Officer | San Francisco, CA |
| n/a Redmile Biopharma Investments II (GP), LLC | Promoter | San Francisco, CA |
Other filings by this issuer (1)
More